The possible role of the Akt signaling pathway in schizophrenia

Brain Research

Volumn 1470, Issue , 2012, Pages 145-158

  Zheng, Wenhua ^a,b   Wang, Haitao ^a   Zeng, Zhiwen ^a   Lin, Jun ^c   Little, Peter J ^d   Srivastava, Lalit K ^e   Quirion, Remi ^e  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUNY Downstate Medical Center   (United States)

^d RMIT UNIVERSITY   (Australia)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Akt; Antipsychotic; Dopamine receptor; Neurodevelopment; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 9; CLOZAPINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DYSBINDIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID; NEU DIFFERENTIATION FACTOR; OLANZAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; POMAGLUMETAD METHIONIL; PROTEIN AKT 1; PROTEIN KINASE B; RISPERIDONE; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

APOPTOSIS; BIPOLAR DISORDER; CELL PROLIFERATION; DEPRESSION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC ASSOCIATION; HUMAN; HUNTINGTON CHOREA; METABOLIC SYNDROME X; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84864588849     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.06.032     Document Type: Review

References (176)

1. M. Anai, N. Shojima, H. Katagiri, T. Ogihara, H. Sakoda, Y. Onishi, H. Ono, M. Fujishiro, Y. Fukushima, N. Horike, A. Viana, M. Kikuchi, N. Noguchi, S. Takahashi, K. Takata, Y. Oka, Y. Uchijima, H. Kurihara, and T. Asano A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis J. Biol. Chem. 280 2005 18525 18535 (Pubitemid 41389103)
2. P.A. Arguello, and J.A. Gogos A signaling pathway AKTing up in schizophrenia J. Clin. Invest. 118 2008 2018 2021 (Pubitemid 351872321)
3. S.E. Arnold, K. Talbot, and C.G. Hahn Neurodevelopment, neuroplasticity, and new genes for schizophrenia Prog. Brain Res. 147 2005 319 345
4. S.N. Bajestan, A.H. Sabouri, M. Nakamura, H. Takashima, M.R. Keikhaee, F. Behdani, M.R. Fayyazi, M.R. Sargolzaee, M.N. Bajestan, Z. Sabouri, E. Khayami, S. Haghighi, S.B. Hashemi, N. Eiraku, H. Tufani, H. Najmabadi, K. Arimura, A. Sano, and M. Osame Association of AKT1 haplotype with the risk of schizophrenia in Iranian population Am. J. Med. Genet. B. Neuropsychiatr. Genet. 141B 2006 383 386 (Pubitemid 43872890)
5. D.T. Balu, G.C. Carlson, K. Talbot, H. Kazi, T.E. Hill-Smith, R.M. Easton, M.J. Birnbaum, and I. Lucki Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function Hippocampus 22 2012 230 240
6. J.M. Beaulieu A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health J. Psychiatry Neurosci. 37 2012 7 16
7. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron The Akt-GSK-3 signaling cascade in the actions of dopamine Trends Pharmacol. Sci. 28 2007 166 172 (Pubitemid 46483722)
8. J.M. Beaulieu, T.D. Sotnikova, S. Marion, R.J. Lefkowitz, R.R. Gainetdinov, and M.G. Caron An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior Cell 122 2005 261 273 (Pubitemid 41032989)
9. J.M. Beaulieu, T.D. Sotnikova, W.D. Yao, L. Kockeritz, J.R. Woodgett, R.R. Gainetdinov, and M.G. Caron Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade Proc. Natl. Acad. Sci. U.S.A. 101 2004 5099 5104 (Pubitemid 38469209)
10. F. Benedetti, S. Poletti, D. Radaelli, A. Bernasconi, R. Cavallaro, A. Falini, C. Lorenzi, A. Pirovano, S. Dallaspezia, C. Locatelli, G. Scotti, and E. Smeraldi Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity Genes Brain Behav. 9 2010 365 371
11. A. Bellacosa, J.R. Testa, S.P. Staal, and P.N. Tsichlis A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region Science 254 1991 274 277 (Pubitemid 21917339)
12. S.K. Bhardwaj, M. Baharnoori, B. Sharif-Askari, A. Kamath, S. Williams, and L.K. Srivastava Behavioral characterization of dysbindin-1 deficient sandy mice Behav. Brain Res. 197 2009 435 441
13. B.K. Bitanihirwe, L. Weber, J. Feldon, and U. Meyer Cognitive impairment following prenatal immune challenge in mice correlates with prefrontal cortical AKT1 deficiency Int. J. Neuropsychopharmacol. 13 2010 981 996
14. B.P. Blum, and J.J. Mann The GABAergic system in schizophrenia Int. J. Neuropsychopharmacol. 5 2002 159 179 (Pubitemid 34662978)
15. P. Boksa Maternal infection during pregnancy and schizophrenia J. Psychiatry Neurosci. 33 2008 183 185 (Pubitemid 351692417)
16. K. Broadbelt, W. Byne, and L.B. Jones Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex Schizophr. Res. 58 2002 75 81 (Pubitemid 35287286)
17. E. Bruel-Jungerman, A. Veyrac, F. Dufour, J. Horwood, S. Laroche, and S. Davis Inhibition of PI3K-Akt signaling blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in the dentate gyrus PLoS One 4 2009 e7901
18. E. Bychkov, M.R. Ahmed, K.N. Dalby, and E.V. Gurevich Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum J. Neurochem. 102 2007 699 711 (Pubitemid 47057295)
19. Y.W. Chen, and W.S. Lai Behavioral phenotyping of v-akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics Neuroscience 174 2010 178 189
20. J.Q. Cheng, C.W. Lindsley, G.Z. Cheng, H. Yang, and S.V. Nicosia The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 24 2005 7482 7492 (Pubitemid 41637988)
21. S.J. Clapcote, T.V. Lipina, J.K. Millar, S. Mackie, S. Christie, F. Ogawa, J.P. Lerch, K. Trimble, M. Uchiyama, Y. Sakuraba, H. Kaneda, T. Shiroishi, M.D. Houslay, R.M. Henkelman, J.G. Sled, Y. Gondo, D.J. Porteous, and J.C. Roder Behavioral phenotypes of Disc1 missense mutations in mice Neuron 54 2007 387 402 (Pubitemid 46671409)
22. P.J. Conn, C.W. Lindsley, and C.K. Jones Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 2009 25 31
23. B. Connor, and M. Dragunow The role of neuronal growth factors in neurodegenerative disorders of the human brain Brain Res. Brain Res. Rev. 27 1998 1 39 (Pubitemid 28300281)
24. J.T. Coyle Glutamate and schizophrenia: beyond the dopamine hypothesis Cell Mol. Neurobiol. 26 2006 365 384
25. J.T. Coyle, and R.S. Duman Finding the intracellular signaling pathways affected by mood disorder treatments Neuron 38 2003 157 160 (Pubitemid 36555643)
26. D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, and B.A. Hemmings Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 378 1995 785 789 (Pubitemid 26004411)
27. T. Damgaard, N. Plath, J.C. Neill, and S.L. Hansen Extrasynaptic GABA (A) receptor activation reverses recognition memory deficits in an animal model of schizophrenia Psychopharmacology (Berlin) 214 2011 403 413
28. J.H. Dey, F. Bianchi, J. Voshol, D. Bonenfant, E.J. Oakeley, and N.E. Hynes Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis Cancer Res. 70 2010 4151 4162
29. A. Di Segni, K. Farin, and R. Pinkas-Kramarski ErbB4 activation inhibits MPP-induced cell death in PC12-ErbB4 cells: involvement of PI3K and Erk signaling J. Mol. Neurosci. 29 2006 257 267
30. J. Dill, H. Wang, F. Zhou, and S. Li Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS J. Neurosci. 28 2008 8914 8928
31. H. Dudek, S.R. Datta, T.F. Franke, M.J. Birnbaum, R. Yao, G.M. Cooper, R.A. Segal, D.R. Kaplan, and M.E. Greenberg Regulation of neuronal survival by the serine-threonine protein kinase Akt Science 275 1997 661 665 (Pubitemid 27061332)
32. J.M. Eckert, S.J. Byer, B.J. Clodfelder-Miller, and S.L. Carroll Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells Glia 57 2009 1501 1520
33. E.S. Emamian, D. Hall, M.J. Birnbaum, M. Karayiorgou, and J.A. Gogos Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia Nat. Genet. 36 2004 131 137 (Pubitemid 38174370)
34. A. Enomoto, N. Asai, T. Namba, Y. Wang, T. Kato, M. Tanaka, H. Tatsumi, S. Taya, D. Tsuboi, K. Kuroda, N. Kaneko, K. Sawamoto, R. Miyamoto, M. Jijiwa, Y. Murakumo, M. Sokabe, T. Seki, K. Kaibuchi, and M. Takahashi Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus Neuron 63 2009 774 787
35. C. Fasano, A. Poirier, L. DesGroseillers, and L.E. Trudeau Chronic activation of the D2 dopamine autoreceptor inhibits synaptogenesis in mesencephalic dopaminergic neurons in vitro Eur. J. Neurosci. 28 2008 1480 1490
36. S.H. Fatemi, and T.D. Folsom The neurodevelopmental hypothesis of schizophrenia, revisited Schizophr. Bull. 35 2009 528 548
37. Z. Freyberg, S.J. Ferrando, and J.A. Javitch Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action Am. J. Psychiatry 167 2010 388 396
38. T. Futamura, K. Toyooka, S. Iritani, K. Niizato, R. Nakamura, K. Tsuchiya, T. Someya, A. Kakita, H. Takahashi, and H. Nawa Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients Mol. Psychiatry 7 2002 673 682 (Pubitemid 34984943)
39. V. Ghiglieri, V. Pendolino, V. Bagetta, C. Sgobio, P. Calabresi, and B. Picconi mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP Exp. Neurol. 226 2010 328 331
40. V. Ghisi, A.J. Ramsey, B. Masri, R.R. Gainetdinov, M.G. Caron, and A. Salahpour Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter Cell. Signal. 21 2009 87 94 189-208
41. D.C. Henderson, X. Fan, B. Sharma, P.M. Copeland, C.P. Borba, R. Boxill, O. Freudenreich, C. Cather, A. Eden, Evins, and D.C. Goff A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia Acta Psychiatr. Scand 119 2009 457 465
42. J.M. Horwood, F. Dufour, S. Laroche, and S. Davis Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat Eur. J. Neurosci. 23 2006 3375 3384
43. O.D. Howes, A.J. Montgomery, M.C. Asselin, R.M. Murray, I. Valli, P. Tabraham, E. Bramon-Bosch, L. Valmaggia, L. Johns, M. Broome, P.K. McGuire, and P.M. Grasby Elevated striatal dopamine function linked to prodromal signs of schizophrenia Arch. Gen. Psychiatry 66 2009 13 20
44. S. Humbert, E.A. Bryson, F.P. Cordelières, N.C. Connors, S.R. Datta, S. Finkbeiner, M.E. Greenberg, and F. Saudou The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt Dev. Cell 2 2002 831 837 (Pubitemid 34650078)
45. M. Ikeda, N. Iwata, T. Suzuki, T. Kitajima, Y. Yamanouchi, Y. Kinoshita, T. Inada, and N. Ozaki Association of AKT1 with schizophrenia confirmed in a Japanese population Biol. Psychiatry 56 2004 698 700 (Pubitemid 39446853)
46. M. Ikeda, N. Iwata, T. Suzuki, T. Kitajima, Y. Yamanouchi, Y. Kinoshiya, Y. Sekine, M. Iyo, M. Harano, T. Komiyama, M. Yamada, I. Sora, H. Ujike, T. Inada, and N. Ozaki Positive association of AKT1 haplotype to Japanese methamphetamine use disorder Int. J. Neuropsychopharmacol. 9 2006 77 81 (Pubitemid 43068336)
47. Y. Ikeda, N. Yahata, I. Ito, M. Nagano, T. Toyota, T. Yoshikawa, Y. Okubo, and H. Suzuki Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia Schizophr. Res. 101 2008 58 66
48. L.F. Jarskog, E.S. Selinger, J.A. Lieberman, and J.H. Gilmore Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation Am. J. Psychiatry 161 2004 109 115 (Pubitemid 38419315)
49. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 148 1991 1301 1308
50. J.D. Jentsch, H. Trantham-Davidson, C. Jairl, M. Tinsley, T.D. Cannon, and A. Lavin Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice Neuropsychopharmacology 34 2009 2601 2608
51. Y. Ji, F. Yang, F. Papaleo, H.X. Wang, W.J. Gao, D.R. Weinberger, and B. Lu Role of dysbindin in dopamine receptor trafficking and cortical GABA function Proc. Natl. Acad. Sci. U.S.A. 106 2009 19593 19598
52. R.D. Jindal, A.K. Pillai, S.P. Mahadik, K. Eklund, D.M. Montrose, and M.S. Keshavan Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia Schizophr. Res. 119 2010 47 51
53. E.G. Jones Cortical development and thalamic pathology in schizophrenia Schizophr. Bull. 23 1997 483 501
54. E. Kahn Genetics and schizophrenic behavior Psychiatr. Q. 52 1980 51 269
55. S.A. Kaladchibachi, B. Doble, N. Anthopoulos, J.R. Woodgett, and A.S. Manoukian Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium J. Circadian Rhythms 5 2007 3
56. S. Kalkstein, I. Hurford, and R.C. Gur Neurocognition in schizophrenia Curr. Top. Behav. Neurosci. 4 2010 373 390
57. U.G. Kang, M.S. Seo, M.S. Roh, Y. Kim, S.C. Yoon, and Y.S. Kim The effects of clozapine on the GSK-3-mediated signaling pathway FEBS Lett. 560 2004 115 119 (Pubitemid 38264303)
58. S. Kapur, and G. Remington Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia Annu. Rev. Med. 52 2001 503 517 (Pubitemid 32195338)
59. F. Karege, N. Perroud, F. Schürhoff, A. Méary, G. Marillier, S. Burkhardt, E. Ballmann, R. Fernandez, S. Jamain, M. Leboyer, R. La, Harpe, and A. Malafosse Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder Genes Brain Behav. 9 2010 503 511
60. M.J. Kempton, D. Stahl, S.C. Williams, and L.E. DeLisi Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies Schizophr. Res. 120 2010 54 62
61. S. Kéri, S. Beniczky, and O. Kelemen Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia Am. J. Psychiatry 167 2010 444 450
62. S. Kéri, I. Seres, O. Kelemen, and G. Benedek Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions Neurochem. Int. 55 2009 606 609
63. J.Y. Kim, C.Y. Liu, F. Zhang, X. Duan, Z. Wen, J. Song, E. Feighery, B. Lu, D. Rujescu St, D. Clair, K. Christian, J.H. Callicott, D.R. Weinberger, H. Song, and G.L. Ming Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia Cell 148 2012 1051 1064
64. S.J. Kim, Z. Zhang, Y.C. Lee, and A.B. Mukherjee Palmitoyl-protein thioesterase-1 deficiency leads to the activation of caspase-9 and contributes to rapid neurodegeneration in INCL Hum. Mol. Genet. 15 2006 1580 1586 (Pubitemid 43904824)
65. T. Kircher, R. Thienel, M. Wagner, M. Reske, U. Habel, T. Kellermann, I. Frommann, S. Schwab, W. Wölwer, M. von Wilmsdorf, D.F. Braus, A. Schmitt, A. Rapp, T. Stöcker, N.J. Shah, F.A. Henn, H. Sauer, W. Gaebel, W. Maier, and F. Schneider Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas Eur. Arch. Psychiatry Clin. Neurosci. 259 2009 72 79
66. S. Koseoglu, Z. Lu, C. Kumar, P. Kirschmeier, and J. Zou AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines Cancer Biol. Ther. 6 2007 755 762 (Pubitemid 47328358)
67. N. Kozlovsky, S. Amar, R.H. Belmaker, and G. Agam Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex Int. J. Neuropsychopharmacol. 9 2006 337 342 (Pubitemid 43780501)
68. N. Kozlovsky, R.H. Belmaker, and G. Agam Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients Am. J. Psychiatry 157 2000 831 833 (Pubitemid 30249669)
69. N. Kozlovsky, R.H. Belmaker, and G. Agam Low GSK-3 activity in frontal cortex of schizophrenic patients Schizophr. Res. 52 2001 101 105 (Pubitemid 32947052)
70. V. Krishnan, M.H. Han, M. Mazei-Robison, S.D. Iñiguez, J.L. Ables, V. Vialou, O. Berton, S. Ghose, H.E. Covington 3rd, M.D. Wiley, R.P. Henderson, R.L. Neve, A.J. Eisch, C.A. Tamminga, S.J. Russo, C.A. Bolaños, and E.J. Nestler AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli Biol. Psychiatry 64 2008 691 700
71. J.H. Krystal, A. Anand, and B. Moghaddam Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia Arch. Gen. Psychiatry 59 2002 663 664 (Pubitemid 34747249)
72. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
73. V. Kumar, M.X. Zhang, M.W. Swank, J. Kunz, and G.Y. Wu Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways J. Neurosci. 25 2005 11288 11299 (Pubitemid 43083703)
74. G. Kuperberg, and S. Heckers Schizophrenia and cognitive function Curr. Opin. Neurobiol. 10 2000 205 210 (Pubitemid 30201113)
75. U.E. Lang, I. Puls, D.J. Muller, N. Strutz-Seebohm, and J. Gallinat Molecular mechanisms of schizophrenia Cell Physiol. Biochem. 20 2007 687 702 (Pubitemid 350059714)
76. M. Laruelle, L.S. Kegeles, and A. Abi-Dargham Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment Ann. N. Y. Acad. Sci. 1003 2003 138 158 (Pubitemid 38083052)
77. G. Lei, Y. Xia, and K.M. Johnson The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration Neuropsychopharmacology 33 2008 1343 1353 (Pubitemid 351521719)
78. J.G. Lee, H.Y. Cho, S.W. Park, M.K. Seo, and Y.H. Kim Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 1001 1006
79. S.H. Lee, W. Chun, P.J. Kong, J.A. Han, B.P. Cho, O.Y. Kwon, H.J. Lee, and S.S. Kim Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus J. Pineal. Res. 40 2006 79 85
80. J.J. Levitt, L. Bobrow, D. Lucia, and P. Srinivasan A selective review of volumetric and morphometric imaging in schizophrenia Curr. Top. Behav. Neurosci. 4 2010 243 281
81. D.A. Lewis, and P. Levitt Schizophrenia as a disorder of neurodevelopment Annu. Rev. Neurosci. 25 2002 409 432 (Pubitemid 34748023)
82. D.A. Lewis, and B. Moghaddam Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations Arch. Neurol. 63 2006 1372 1376 (Pubitemid 44547546)
83. Y.C. Li, D. Xi, J. Roman, Y.Q. Huang, and W.J. Gao Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex J. Neurosci. 29 2009 15551 15563
84. Z. Li, J. Jo, J.M. Jia, S.C. Lo, D.J. Whitcomb, S. Jiao, K. Cho, and M. Sheng Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization Cell 141 2010 859 871
85. J.A. Lieberman Dopamine partial agonists: a new class of antipsychotic CNS Drugs 18 2004 251 267 (Pubitemid 38393435)
86. T.V. Lipina, M. Niwa, H. Jaaro-Peled, P.J. Fletcher, P. Seeman, A. Sawa, and J.C. Roder Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia Genes Brain Behav. 9 2010 777 789
87. T.V. Lipina, O. Kaidanovich-Beilin, S. Patel, M. Wang, S.J. Clapcote, F. Liu, J.R. Woodgett, and J.C. Roder Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3 Synapse 65 2011 234 248
88. J.E. Lisman, J.T. Coyle, R.W. Green, D.C. Javitt, F.M. Benes, S. Heckers, and A.A. Grace Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia Trends Neurosci. 31 2008 234 242
89. Y.L. Liu, C.S. Fann, C.M. Liu, J.Y. Wu, S.I. Hung, H.Y. Chan, J.J. Chen, C.C. Pan, S.K. Liu, M.H. Hsieh, T.J. Hwang, W.C. Ouyang, C.Y. Chen, J.J. Lin, F.H. Chou, C.M. Chueh, W.M. Liu, M.M. Tsuang, S.V. Faraone, M.T. Tsuang, W.J. Chen, and H.G. Hwu Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population Psychiatr. Genet. 16 2006 39 41 (Pubitemid 44481219)
90. J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, and P.A. Dennis Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11 2008 32 50
91. M. Makinodan, K. Tatsumi, T. Manabe, T. Yamauchi, E. Makinodan, H. Matsuyoshi, S. Shimoda, Y. Noriyama, T. Kishimoto, and A. Wanaka Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring J. Neurosci. Res. 86 2008 2190 2200
92. Y. Mao, X. Ge, C.L. Frank, J.M. Madison, A.N. Koehler, M.K. Doud, C. Tassa, E.M. Berry, T. Soda, K.K. Singh, T. Biechele, T.L. Petryshen, R.T. Moon, S.J. Haggarty, and L.H. Tsai Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling Cell 136 2009 1017 1031
93. S. Marenco, and D.R. Weinberger The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave Dev. Psychopathol. 12 2000 501 527
94. B.M. Marte, and J. Downward PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond Trends Biochem. Sci. 22 1997 355 358
95. A. Mathur, M.H. Law, I.L. Megson, D.J. Shaw.; and J. Wei Genetic association of the AKT1 gene with schizophrenia in a British population Psychiatr. Genet. 20 2010 118 122
96. M. Medina, and J. Avila Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease Curr. Pharm. Des. 16 2010 2790 2798
97. R. Meier, and B.A. Hemmings Regulation of protein kinase B J. Recept. Signal. Transduct. Res. 19 1999 121 128 (Pubitemid 29152177)
98. L. Mei, and W.C. Xiong Neuregulin 1 in neural development, synaptic plasticity and schizophrenia Nat. Rev. Neurosci. 9 2008 437 452 (Pubitemid 351704944)
99. M. Mezler, H. Geneste, L. Gault, and G.J. Marek LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia Curr. Opin. Investig. Drugs 11 2010 833 845
100. K.J. Mitchell, and D.J. Porteous Rethinking the genetic architecture of schizophrenia Psychol. Med. 41 2011 19 32
101. J.C. Neill, S. Barnes, S. Cook, B. Grayson, N.F. Idris, S.L. McLean, S. Snigdha, L. Rajagopal, and M.K. Harte Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism Pharmacol. Ther. 128 2010 419 432
102. K. Ning, C. Drepper, C.F. Valori, M. Ahsan, M. Wyles, A. Higginbottom, T. Herrmann, P. Shaw, M. Azzouz, and M. Sendtner PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons Hum. Mol. Genet. 19 2010 3159 3168
103. T. Numakawa, Y. Yagasaki, T. Ishimoto, T. Okada, T. Suzuki, N. Iwata, N. Ozaki, T. Taguchi, M. Tatsumi, K. Kamijima, R.E. Straub, D.R. Weinberger, H. Kunugi, and R. Hashimoto Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia Hum. Mol. Genet. 13 2004 2699 2708 (Pubitemid 39485418)
104. M.C. O'Donovan, N.J. Craddock, and M.J. Owen Genetics of psychosis; insights from views across the genome Hum. Genet. 126 2009 3 12
105. T. Ohtsuki, T. Inada, and T. Arinami Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population Mol. Psychiatry 9 2004 981 983
106. K. Oishi, K. Watatani, Y. Itoh, H. Okano, F. Guillemot, K. Nakajima, and Y. Gotoh Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1 Proc. Natl. Acad. Sci. U.S.A. 106 2009 13064 13069
107. Y. Ozeki, T. Tomoda, J. Kleiderlein, A. Kamiya, L. Bord, K. Fujii, M. Okawa, N. Yamada, M.;.E. Hatten, S.H. Snyder, C.A. Ross, and A. Sawa Disrupted-in-schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth Proc. Natl. Acad. Sci. U.S.A. 100 2003 289 294 (Pubitemid 36078067)
108. F. Papaleo, and D.R. Weinberger Dysbindin and schizophrenia: it's dopamine and glutamate all over again Biol. Psychiatry 69 2011 2 4
109. S.W. Park, J.G. Lee, B.G. Kong, S.J. Lee, C.H. Lee, J.I. Kim, and Y.H. Kim Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia Psychiatry Clin. Neurosci. 63 2009 433 439
110. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 13 2007 1102 1107 (Pubitemid 47517511)
111. S. Peineau, C. Taghibiglou, C. Bradley, T.P. Wong, L. Liu, J. Lu, E. Lo, D. Wu, E. Saule, T. Bouschet, P. Matthews, J.T. Isaac, Z.A. Bortolotto, Y.T. Wang, and G.L. Collingridge LTP inhibits LTD in the hippocampus via regulation of GSK3beta Neuron 53 2007 703 717 (Pubitemid 46283369)
112. K. Pennington, P. Dicker, L. Hudson, and D.R. Cotter Evidence for reduced neuronal somal size within the insular cortex in schizophrenia, but not in affective disorders Schizophr. Res. 106 2008 164 171
113. A. Pereira, G. Fink, and S. Sundram Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor J. Mol. Neurosci. 39 2009 185 198
114. O.P. Pietiläinen, T. Paunio, A. Loukola, A. Tuulio-Henriksson, T. Kieseppä, P. Thompson, A.W. Toga, T.G. van Erp, K. Silventoinen, P. Soronen, W. Hennah, J.A. Turunen, J. Wedenoja, O.M. Palo, K. Silander, J. Lönnqvist, J. Kaprio, T.D. Cannon, and L. Peltonen Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B 2009 683 692
115. I. Pitha-Rowe, K. Liby, D. Royce, and M. Sporn Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest. Ophthalmol. Vis. Sci. 50 2009 5339 5347
116. P. Polak, and M.N. Hall mTOR and the control of whole body metabolism Curr. Opin. Cell Biol. 21 2009 209 218
117. A. Polter, S. Yang, A.A. Zmijewska, T. van Groen, J.H. Paik, R.A. Depinho, S.L. Peng, R.S. Jope, and X. Li Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation Biol. Psychiatry 65 2009 150 159
118. A.P. Popkie, L.C. Zeidner, A.M. Albrecht, A. D'Ippolito, S. Eckardt, D.E. Newsom, J. Groden, B.W. Doble, B. Aronow, K.J. McLaughlin, P. White, and C.J. Phiel Phosphatidylinositol 3-Kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci J. Biol. Chem. 285 2010 41337 41347
119. D.E. Read, and A.M. Gorman Involvement of Akt in neurite outgrowth Cell Mol. Life Sci. 66 2009 2975 2984
120. B.P. Riley, A. Makoff, M. Mogudi-Carter, T. Jenkins, R. Williamson, D. Collier, and R. Murray Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families Am. J. Med. Genet. 96 2000 196 201 (Pubitemid 30180863)
121. E.N. Rizos, P.G. Michalopoulou, N. Siafakas, N. Stefanis, A. Douzenis, I. Rontos, E. Laskos, A. Kastania, V. Zoumpourlis, and L. Lykouras Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia Neuropsychobiology 62 2010 87 90
122. M.S. Roh, M.S. Seo, Y. Kim, S.H. Kim, W.J. Jeon, Y.M. Ahn, U.G. Kang, Y.S. Juhnn, and Y.S. Kim Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex Exp. Mol. Med. 39 2007 353 360 (Pubitemid 47037626)
123. C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, and D.J. Glass Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways Nat. Cell Biol. 3 2001 1009 1013 (Pubitemid 34428746)
124. C.A. Ross, R.L. Margolis, S.A. Reading, M. Pletnikov, and J.T. Coyle Neurobiology of schizophrenia Neuron 52 2006 139 153 (Pubitemid 44466356)
125. J.K. Rybakowski BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia Pharmacogenomics 9 2008 1589 1593
126. M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, A. Picard, K. Walsh, S. Schiaffino, S.H. Lecker, and A.L. Goldberg Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy Cell 117 2004 399 412 (Pubitemid 38534545)
127. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101 (Pubitemid 40262113)
128. M.P. Scheid, and J.R. Woodgett PKB/AKT: functional insights from genetic models Nat. Rev. Mol. Cell Biol. 2 2001 760 768 (Pubitemid 33679838)
129. M. Schubert, D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert, T. Kondo, J. Alber, N. Galldiks, E. Küstermann, S. Arndt, A.H. Jacobs, W. Krone, C.R. Kahn, and J.C. Brüning Role for neuronal insulin resistance in neurodegenerative diseases Proc. Natl. Acad. Sci. U.S.A. 101 2004 3100 3105 (Pubitemid 38327741)
130. S.G. Schwab, B. Hoefgen, C. Hanses, M.B. Hassenbach, M. Albus, B. Lerer, M. Trixler, W. Maier, and D.B. Wildenauer Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families Biol. Psychiatry 58 2005 446 450 (Pubitemid 41393606)
131. P. Seeman, H.C. Guan, and H.H. Van Tol Dopamine D4 receptors elevated in schizophrenia Nature 365 1993 441 445 (Pubitemid 23311038)
132. P. Seeman, D. Weinshenker, R. Quirion, L.K. Srivastava, S.K. Bhardwaj, D.K. Grandy, R.T. Premont, T.D. Sotnikova, P. Boksa, M. El-Ghundi, B.F. O'dowd, S.R. George, M.L. Perreault, P.T. Männistö, S. Robinson, R.D. Palmiter, and T. Tallerico Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis Proc. Natl. Acad. Sci. U.S.A. 2 2005 3513 3518 (Pubitemid 40328076)
133. L.D. Selemon, and P.S. Goldman-Rakic The reduced neuropil hypothesis: a circuit based model of schizophrenia Biol. Psychiatry 45 1999 17 25 (Pubitemid 29049200)
134. P. Sen, S. Mukherjee, D. Ray, and S. Raha Involvement of the Akt/PKB signaling pathway with disease processes Mol. Cell Biochem. 253 2003 241 246 (Pubitemid 37321731)
135. I. Seres, O. Kelemen, G. Benedek, and S. Kéri Neuregulin 1-induced AKT phosphorylation in monozygotic twins discordant for schizophrenia Neurochem. Int. 56 2010 906 910
136. S. Seshadri, A. Kamiya, Y. Yokota, I. Prikulis, S. Kano, A. Hayashi-Takagi, A. Stanco, T.Y. Eom, S. Rao, K. Ishizuka, P. Wong, C. Korth, E.S. Anton, and A. Sawa Disrupted-in-schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade Proc. Natl. Acad. Sci. U.S.A. 107 2010 5622 5627
137. R.A. Shih, P.L. Belmonte, and P.P. Zandi A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders Int. Rev. Psychiatry 16 2004 260 283 (Pubitemid 39657837)
138. C. Skurk, Y. Izumiya, H. Maatz, P. Razeghi, I. Shiojima, M. Sandri, K. Sato, L. Zeng, S. Schiekofer, D. Pimentel, S. Lecker, H. Taegtmeyer, A.L.
139. R.P. Souza, M.A. Romano-Silva, J.A. Lieberman, H.Y. Meltzer, A.H. Wong, and J.L. Kennedy Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response Psychopharmacology (Berlin) 200 2008 177 186
140. S.M. Stahl Symptoms and circuits, part 3: schizophrenia J. Clin. Psychiatry 65 2004 8 9
141. R.E. Straub, Y. Jiang, C.J. MacLean, Y. Ma, B.T. Webb, M.V. Myakishev, C. Harris-Kerr, B. Wormley, H. Sadek, B. Kadambi, A.J. Cesare, A. Gibberman, X. Wang, F.A. O'Neill, D. Walsh, and K.S. Kendler Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia Am. J. Hum. Genet. 71 2002 337 348 (Pubitemid 34800250)
142. L. Sui, J. Wang, and B.M. Li Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex Learn. Mem. 15 2008 762 776
143. L. Swiech, M. Perycz, A. Malik, and J. Jaworski Role of mTOR in physiology and pathology of the nervous system Biochim. Biophys. Acta 1784 2008 116 132
144. A. Szamosi, O. Kelemen, and S. Kéri Hippocampal volume and the AKT signaling system in first-episode schizophrenia J. Psychiatr. Res. 46 2012 279 284
145. A. Takashima GSK-3 is essential in the pathogenesis of Alzheimer's disease J. AlzheimersDis. 9 2006 309 317 (Pubitemid 44253325)
146. S.J. Tang, G. Reis, H. Kang, A.C. Gingras, N. Sonenberg, and E.M. Schuman A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus Proc. Natl. Acad. Sci. U.S.A. 99 2002 467 472 (Pubitemid 34060384)
147. H.Y. Tan, K.K. Nicodemus, Q. Chen, Z. Li, J.K. Brooke, R. Honea, B.S. Kolachana, R.E. Straub, A. Meyer-Lindenberg, Y. Sei, V.S. Mattay, J.H. Callicott, and D.R. Weinberger Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans J. Clin. Invest. 118 2008 2200 2208 (Pubitemid 351872338)
148. D.L. Thiselton, V.I. Vladimirov, P.H. Kuo, J. McClay, B. Wormley, A. Fanous, F.A. O'Neill, D. Walsh, E.J. Van den Oord, K.S. Kendler, and B.P. Riley AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families Biol. Psychiatry 63 2008 449 457 (Pubitemid 351220788)
149. S. Timmons, M.F. Coakley, A.M. Moloney, and C. O'Neill Akt signal transduction dysfunction in Parkinson's disease Neurosci. Lett. 467 2009 30 35
150. J.R. Tregellas, D.B. Davalos, D.C. Rojas, M.C. Waldo, L. Gibson, K. Wylie, Y.P. Du, and R. Freedman Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia Schizophr. Res. 92 2007 262 272 (Pubitemid 46578285)
151. J.R. Tregellas, A. Olincy, L. Johnson, J. Tanabe, S. Shatti, L.F. Martin, D. Singel, Y.P. Du, F. Soti, W.R. Kem, and R. Freedman Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia Neuropsychopharmacology 35 2010 938 942
152. M. Tsuang Schizophrenia: genes and environment Biol. Psychiatry 47 2000 210 220 (Pubitemid 30077397)
153. M.H. Tuszynski Growth-factor gene therapy for neurodegenerative disorders Lancet Neurol. 1 2002 51 57 (Pubitemid 37159198)
154. L. Urigüen, M.J. García-Fuster, L.F. Callado, B. Morentin, R. La, Harpe.; V. Casadó, C. Lluis, R. Franco, J.A. García-Sevilla, and J.J. Meana Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment Psychopharmacology (Berlin) 206 2009 313 324
155. N.J. Van Beveren, J.J. van der Spelt, L. de Haan, and D. Fekkes Schizophrenia-associated neural growth factors in peripheral blood. A review Eur. Neuropsychopharmacol. 16 2006 469 480 (Pubitemid 44311003)
156. J. van Os, and S. Kapur Schizophrenia Lancet 374 2009 635 645
157. J. van Os, B.P. Rutten, and R. Poulton Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions Schizophr. Bull. 34 2008 1066 1082
158. G. Venkatasubramanian, S. Chittiprol, N. Neelakantachar, M.N. Naveen, J. Thirthall, B.N. Gangadhar, and K.T. Shetty Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia Am. J. Psychiatry 164 2007 1557 1560 (Pubitemid 350069735)
159. G. Venkatasubramanian, S. Chittiprol, N. Neelakantachar, T. Shetty, and B.N. Gangadhar Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study Schizophr. Res. 119 2010 131 137
160. A. Vita, L. De Peri, C. Silenzi, and M. Dieci Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies Schizophr. Res. 82 2006 75 88 (Pubitemid 43202650)
161. K. Waite, and B.J. Eickholt The neurodevelopmental implications of PI3K signaling Curr. Top. Microbiol. Immunol. 346 2010 245 265
162. Q. Wang, L. Liu, L. Pei, W. Ju, G. Ahmadian, J. Lu, Y. Wang, F. Liu, and Y.T. Wang Control of synaptic strength, a novel function of Akt Neuron 38 2003 915 928 (Pubitemid 36782383)
163. W. Wei, X. Wang, and J.W. Kusiak Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection J. Biol. Chem. 277 2002 17649 17656 (Pubitemid 34967568)
164. D.R. Weinberger From neuropathology to neurodevelopment Lancet 346 1995 552 557
165. C.S. Weickert, T.M. Hyde, B.K. Lipska, M.M. Herman, D.R. Weinberger, and J.E. Kleinman Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia Mol. Psychiatry 8 2003 592 610 (Pubitemid 36898018)
166. J.A. Wofford, H.L. Wieman, S.R. Jacobs, Y. Zhao, and J.C. Rathmell IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival Blood 111 2008 2101 2111 (Pubitemid 351451522)
167. B.T. Woods, K.E. Ward, and E.H. Johnson Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment Schizophr. Res. 73 2005 221 228 (Pubitemid 40093882)
168. M.Q. Xu, Q.H. Xing, Y.L. Zheng, S. Li, J.J. Gao, G. He, T.W. Guo, G.Y. Feng, F. Xu, and L. He Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population J. Clin. Psychiatry 68 2007 1358 1367 (Pubitemid 47524515)
169. N. Yasui-Furukori, Y. Sato, H. Furukori, M. Saito, T. Nakagami, and S. Kaneko Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine J. Clin. Psychiatry 70 2009 95 100
170. A. Yoshii, and M. Constantine-Paton BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation Nat. Neurosci. 10 2007 702 711 (Pubitemid 46828509)
171. D. Zemke, S. Azhar, and A. Majid The mTOR pathway as a potential target for the development of therapies against neurological disease Drug News Perspect 20 2007 495 499 (Pubitemid 351182792)
172. Z. Zhao, H. Ksiezak-Reding, S. Riggio, V. Haroutunian, and G.M. Pasinetti Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction Schizophr. Res. 84 2006 1 14
173. W.H. Zheng, S. Bastianetto, F. Mennicken, W. Ma, and S. Kar Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures Neuroscience 115 2002 201 211 (Pubitemid 35232701)
174. W.H. Zheng, S. Kar, and R. Quirion Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells J. Biol. Chem. 275 2000 39152 39158 (Pubitemid 32058931)
175. W.H. Zheng, and R. Quirion Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival J. Neurochem. 89 2004 844 852 (Pubitemid 38684732)
176. W.H. Zheng, and R. Quirion Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells BMC Neurosci. 7 2006 51